Clin2
NCT07708181Possibly a fitNot yet recruiting

SSGJ-613 injection for gout flare prevention

Gout Arthritis

Treatments studied

Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism clinical trials.

This trial tests an injection called SSGJ-613 to see if it can prevent gout flares in people who are starting a medication to lower uric acid. It's for people with frequent gout attacks.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
200 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must be 18 to 75 years old.
  • Your Body Mass Index (BMI) must be 40 or lower.
  • You need to have gout diagnosed by a doctor using specific criteria.
  • You must have had at least 4 gout attacks in the past year.
  • You cannot have severe kidney problems, active infections, or be unable to get subcutaneous injections.
  • You must not have received a live vaccine in the last 8 weeks.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07346079Recruiting· Phase 4
Corticotropin gel for acute gout flares

This study tests two doses of a medicine called Purified Cortrophin Gel for people having a gout flare that started in the last 5 days. It might be an option if other treatments haven't worked or aren't safe for you.

Boston, Massachusetts
NCT07369622Not yet recruiting· Phase 4
Testing allergy gene before gout treatment

This trial checks if testing for a specific gene (HLA-B*58:01) before starting gout medication can prevent severe allergic reactions. It compares standard care with a gene-guided approach to see which is safer and works better.

NCT06863701Recruiting· Phase 3
Combination therapy for acute gout flare

This trial tests a combination of two medicines, etoricoxib and betamethasone, for quickly treating a painful gout flare. It is for people who have had gout before and whose current attack started within two days.

Mexico City
NCT07587684Recruiting· Phase 1
Testing IN026 for Hard-to-Treat Gout

This study tests a new drug called IN026 for people with refractory gout—gout that doesn't respond well to current treatments and causes severe symptoms. The goal is to see if IN026 can lower uric acid levels and reduce gout attacks.

Wuhan
NCT07145229Recruiting· Phase 2
Testing a new drug for acute gout flares

This trial tests a new medication, ABP-745, for people having an acute gout flare. It aims to see if the drug is safe and helps reduce pain and inflammation.

Peoria, Arizona
NCT06629376Recruiting· Phase 1
Testing a new gout drug for safety and effect on uric acid

This trial tests an experimental drug, SSS11, to see if it is safe and how it affects uric acid levels in people with gout and high uric acid. You may not take other gout medicines during the study.

Shanghai

Hear when a new Gout Arthritis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.